Results 111 to 120 of about 681,398 (156)

Effects of oral administration of nonselective Trk inhibitor on bladder overactivity in rodent models of prostatic inflammation. [PDF]

Prostate
Igarashi T, Mizoguchi S, Matsuoka K, Kamijo T, Kawano S, Furuta A, Suzuki Y, Kimura T, Pascal LE, Wang Z, Yoshimura N.   +10 more
europepmc   +1 more source

Bioanalytical assay for the novel TRK inhibitor selitrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry

, 2019
Selitrectinib is a next generation tropomyosin receptor kinase (TRK) inhibitor developed to overcome acquired resistance to first generation TRK inhibitors. The drug is a cyclic analogue of larotrectinib. An existing bioanalytical assay for larotrectinib
Sparidans, Rolf W, Schinkel, Alfred H, Beijnen, Jos H, Li, Wenlong   +3 more
core  

Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion. [PDF]

Ann Oncol, 2019
Bielack SS, Cox MC, Nathrath M, Apel K, Blattmann C, Holl T, Jenewein R, Klenk U, Klothaki P, Müller-Abt P, Ortega-Lawerenz S, Reynolds M, Scheer M, Simon-Klingenstein K, Stegmaier S, Tupper R, Vokuhl C, von Kalle T.   +17 more
europepmc   +1 more source

Demonstration of an anti-hyperalgesic effect of a novel pan-Trk inhibitor PF-06273340 in a battery of human evoked pain models. [PDF]

Br J Clin Pharmacol, 2018
Loudon P, Siebenga P, Gorman D, Gore K, Dua P, van Amerongen G, Hay JL, Groeneveld GJ, Butt RP.   +8 more
europepmc   +1 more source

Zidesamtinib (Jideytro®): a new selective, brain-penetrant ROS1 inhibitor approved for the treatment of ROS1-positive non-small cell lung cancer. [PDF]

Med Chem Res
Lee S, Hu L.
europepmc   +1 more source

Larotrectinib in TRK fusion differentiated thyroid carcinoma: updated trial data. [PDF]

Endocr Relat Cancer
Waguespack SG, Brose MS, Lin JJ, McDermott R, Almubarak M, Bauman J, Casanova M, Kummar S, Lee SH, Rieke DT, Oh DY, Qi C, Neu N, Burcoveanu DI, Mussi CE, Drilon A, Hong DS, Cabanillas ME.   +17 more
europepmc   +1 more source

Adult Sarcomas with NTRK Fusions: Clinicopathologic and Genomic Heterogeneity. [PDF]

Cancers (Basel)
Schwartz M, Sweeney K, Smith SC, Angara K, Reynolds C, Pappo AS, Elliott A, Oberley MJ, Evans MG, Bahrami A.   +9 more
europepmc   +1 more source

TRK immunohistochemistry in pediatric rhabdomyosarcomas: diagnostic and prognostic utility and limitations. [PDF]

Pathol Oncol Res
Lajti R, Dezső K, Sápi Z, Papp G, Mohás A, Bukovszky B, Szabó S, Felkai L, Csóka M.   +8 more
europepmc   +1 more source

High-Grade Endometrial Stromal Sarcoma with <i>NTRK</i> Fusion and Response to Larotrectinib: A Case Report. [PDF]

J Clin Med
Bar-Noy T, Lozano-Franco R, Nagaria TS, Brodeur MN, Salvador S, Lau S.   +5 more
europepmc   +1 more source